• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dissolvable microneedle patch for flu vaccine succeeds in Phase I

June 28, 2017 By Sarah Faulkner

Microneedle flu vaccine patchDissolvable microneedle patches that deliver the flu vaccine could provide a safe and cost-effective alternative to traditional immunization methods, according to the results from a Phase I trial published in The Lancet this week.

The study enrolled adults ages 18 to 49 and randomly assigned them to receive a single dose of inactivated flu vaccine via microneedle patch, intramuscular injection or a placebo by microneedle patch – all administered by a healthcare practitioner. The 4th group self-administered an inactivated flu vaccine using a microneedle patch.

The study’s primary safety outcome endpoints were the rate of product-related serious adverse events within 180 days and solicited injection site and systemic reactogenicity from days 0 to 7.

Immunogenicity outcomes included anitbody titres at day 28 and the percentages of seroconversion and seroprotection, according to the researchers.

Among the 100 participants, there were no treatment-related serious adverse events and no new-onset chronic illnesses. Also, the microneedle patch and the intramuscular injection performed similarly at day 28 for the H1N1 strain, the H3N2 strain and the B strain. Similar results were reported for the participants who self-administered the vaccine using a microneedle patch.

The patches were designed at Georgia Institute of Technology, which conducted the study in collaboration with Emory University.

“It’s very gratifying and exciting to have these patches tested in a clinical trial, and with a result that turned out so well. We now need to follow this study with a Phase II clinical trial involving more people, and we hope that will happen soon,” senior co-author Mark Prausnitz said in prepared remarks.

Prausnitz co-founded Micron Biomedical that is licensing patents related to this study, the university reported.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: emoryuniversity, Georgia Institute of Technology

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS